drugset / Trial / NCT04602975
A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a
Phase 2
Completed
248 enrolled
Institut Pasteur
ClinWin Research · collabGates Medical Research Institute · collabHenry M. Jackson Foundation Medical Research International · collabParexel · collabWalter Reed Army Institute of Research (WRAIR) · collabWellcome Trust · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A study among adults, children and infants in Kenya to determine if a new type of glycoconjugate vaccine incorporating a synthetic carbohydrate component is safe and induces immunity against Shigella.
Timeline
- Start
- 2020-10-06
- Primary completion
- 2023-04-12
- Completion
- 2023-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SF2a-TT15 | Vaccine | 2 ug | Intramuscular |
| Subject | SF2a-TT15 | Vaccine | 10 ug | Intramuscular |
Indications
No indication recorded.